A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
RO5027838
RO5027838
RO5093151
RO5093151
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
- adult patients, 35-65 years of age;
- type 2 diabetes for >=3 months;
- treated for >=3 months with stable dose of metformin >=1.5g/day or maximum tolerated dose.
Exclusion Criteria:
- history of diabetic ketoacidosis;
- currently or previously treated with insulin;
- currently or within previous 6 months treated with a thiazolidinedione or dual peroxisome proliferator activated receptor (PPAR) agonist;
- treated with lipoprotein-modifying therapy within a month before screening.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Arm Label
Placebo
RO5027838 200mg
RO5027838 50mg
RO5093151 10mg
RO5093151 400mg
Arm Description
Outcomes
Primary Outcome Measures
Absolute change in mean daily plasma glucose
Secondary Outcome Measures
Fasting plasma glucose
Post-prandial glucose and insulin
Insulin sensitivity, beta cell function, lipid profile, HbA1C
Adverse events, lab parameters, vital signs, body weight
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00823680
Brief Title
A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Official Title
Multi-center, Randomized, Double-blind, 5-arm Parallel Group, Placebo Controlled 4 Week Study to Investigate the Safety, Tolerability and Efficacy of Two Doses Each (Near to Maximum Tolerated Dose and Lower Dose) of RO5093151 Administered Twice Daily (BID Regimen) and RO5027838 Administered Once da
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
August 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This 5 arm study will evaluate the efficacy and safety of RO5093151 and RO5027838 in patients with type 2 diabetes mellitus on a stable dose of metformin. After a 4 week pre-randomization period for glucose control, patients will be randomized to one of 5 groups to receive a)RO5093151 400mg po bid b)RO5093151 10mg po bid c)RO5027838 200mg po qd d)RO5027838 50mg po qd or e)placebo po bid for 4 weeks. The anticipated time on study treatment is < 3 months, and the target sample size is 100-500 individuals.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
110 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
RO5027838 200mg
Arm Type
Experimental
Arm Title
RO5027838 50mg
Arm Type
Experimental
Arm Title
RO5093151 10mg
Arm Type
Experimental
Arm Title
RO5093151 400mg
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
po bid for 4 weeks
Intervention Type
Drug
Intervention Name(s)
RO5027838
Intervention Description
200mg po qd for 4 weeks
Intervention Type
Drug
Intervention Name(s)
RO5027838
Intervention Description
50mg po bid for 4 weeks
Intervention Type
Drug
Intervention Name(s)
RO5093151
Intervention Description
400mg po bid for 4 weeks
Intervention Type
Drug
Intervention Name(s)
RO5093151
Intervention Description
10mg po bid for 4 weeks
Primary Outcome Measure Information:
Title
Absolute change in mean daily plasma glucose
Time Frame
From baseline to day 27
Secondary Outcome Measure Information:
Title
Fasting plasma glucose
Time Frame
Baseline, and weeks 1, 2, 3 and 4
Title
Post-prandial glucose and insulin
Time Frame
Baseline, weeks 2 and 4
Title
Insulin sensitivity, beta cell function, lipid profile, HbA1C
Time Frame
At baseline, and at planned visits up to week 4
Title
Adverse events, lab parameters, vital signs, body weight
Time Frame
At baseline, and at planned visits up to week 4
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adult patients, 35-65 years of age;
type 2 diabetes for >=3 months;
treated for >=3 months with stable dose of metformin >=1.5g/day or maximum tolerated dose.
Exclusion Criteria:
history of diabetic ketoacidosis;
currently or previously treated with insulin;
currently or within previous 6 months treated with a thiazolidinedione or dual peroxisome proliferator activated receptor (PPAR) agonist;
treated with lipoprotein-modifying therapy within a month before screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
330014
Country
United States
City
Graz
ZIP/Postal Code
8036
Country
Austria
City
München
ZIP/Postal Code
80636
Country
Germany
City
Neuss
ZIP/Postal Code
41460
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
We'll reach out to this number within 24 hrs